Quality of life and cost-effectiveness of convalescent plasma compared to standard care for hospitalized COVID-19 patients in the CONCOR-1 trial.
immunology (other than RBC serology)
plasma derivatives
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
revised:
22
01
2024
received:
06
09
2023
accepted:
26
02
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings. Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L were measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses costs from this population. 940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, EQ-5D-5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms, respectively (p = .46). The incremental cost was $4458 and the incremental quality-adjusted life day was -0.078. Convalescent plasma was less effective and more costly than standard care in treating hospitalized COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings.
METHODS
METHODS
Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L were measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses costs from this population.
RESULTS
RESULTS
940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, EQ-5D-5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms, respectively (p = .46). The incremental cost was $4458 and the incremental quality-adjusted life day was -0.078.
DISCUSSION
CONCLUSIONS
Convalescent plasma was less effective and more costly than standard care in treating hospitalized COVID-19.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIHR
ID : 447352
Pays : Canada
Informations de copyright
© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid‐19. N Engl J Med. 2021;384(11):1015–1027.
Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, et al. Convalescent plasma for adults with acute COVID‐19 respiratory illness (CONCOR‐1): study protocol for an international, multicentre, randomized, open‐label trial. Trials. 2021;22(1):323.
Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma for hospitalized patients with COVID‐19: an open‐label, randomized controlled trial. Nat Med. 2021;27(11):2012–2024.
Recovery Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised controlled, open‐label, platform trial. Lancet. 2021;397(10289):2049–2059.
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy and safety of COVID‐19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):115–126.
Axfors C, Janiaud P, Schmitt AM, van't Hooft J, Smith ER, Haber NA, et al. Association between convalescent plasma treatment and mortality in COVID‐19: a collaborative systematic review and meta‐analysis of randomized clinical trials. BMC Infect Dis. 2021;21(1):1170.
Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al‐Beidh F, Annane D, et al. Effect of convalescent plasma on organ support–free days in critically ill patients with COVID‐19: a randomized clinical trial. JAMA. 2021;326(17):1690–1702.
Don H, Michael D, Federico A, Esther de B‐G, Andrew HB, Chris C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L). Qual Life Res. 2011;20(10):1727–1736.
Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, et al. A time trade‐off‐derived value set of the EQ‐5D‐5L for Canada. Med Care. 2016;54(1):98–105.
Information, CIfH. COVID‐19 hospitalization and emergency department statistics [product release]. 2022.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost‐effectiveness acceptability curves. Health Econ. 2001;10(8):779–787.
Korley FK, Durkalski‐Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al. Early convalescent plasma for high‐risk outpatients with Covid‐19. N Engl J Med. 2021;385(21):1951–1960.
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database Syst Rev. 2020;7(7):Cd013600.
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high‐titer plasma therapy to prevent severe Covid‐19 in older adults. N Engl J Med. 2021;384(7):610–618.
Hamilton FW, Lee T, Arnold DT, Lilford R, Hemming K. Is convalescent plasma futile in COVID‐19? A Bayesian re‐analysis of the RECOVERY randomized controlled trial. Int J Infect Dis. 2021;109:114–117.
Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ‐5D‐5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647–673.
de Oliveira JF, de Ávila RE, de Oliveira NR, da Cunha Severino Sampaio N, Botelho M, Gonçalves FA, et al. Persistent symptoms, quality of life, and risk factors in long COVID: a cross‐sectional study of hospitalized patients in Brazil. Int J Infect Dis. 2022;122:1044–1051.
Tsuzuki S, Miyazato Y, Terada M, Morioka S, Ohmagari N, Beutels P. Impact of long‐COVID on health‐related quality of life in Japanese COVID‐19 patients. Health Qual Life Outcomes. 2022;20(1):125.
Lang‐Meli J, Fuchs J, Mathé P, Ho HE, Kern L, Jaki L, et al. Case series: convalescent plasma therapy for patients with COVID‐19 and primary antibody deficiency. J Clin Immunol. 2022;42(2):253–265.
Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent plasma in COVID‐19 patients with immunosuppression. Transfusion. 2021;61(8):2503–2511.